$CRMD News

CorMedix Stock Jumps As DefenCath Fuels Q1 Beat, 2026 Outlook Raised

CorMedix Inc. (CRMD) Q1 2026 Earnings Call Transcript

CorMedix Inc (NASDAQ:CRMD) Surges After Blowout Q1 Earnings Beat and Raised Guidance

Cormedix Raises FY2026 Sales Guidance from $300.000M-$320.000M to $325.000M-$345.000M vs $308.224M Est

Cormedix Q1 2026 Earnings Call Transcript

Cormedix Q1 Adj. EPS $0.43 Beats $0.36 Estimate, Sales $127.427M Beat $105.017M Estimate

RBC Capital Maintains Outperform on Cormedix, Raises Price Target to $14

Citizens Reiterates Market Outperform on Cormedix, Maintains $19 Price Target

Leerink Partners Maintains Outperform on Cormedix, Raises Price Target to $14

CorMedix Eyes $2 Billion Market With Encouraging Data From Fungal Infection Study

Needham Maintains Buy on Cormedix, Raises Price Target to $15

CorMedix Announces Phase III Topline Results From Global ReSPECT Clinical Trial Evaluating REZZAYO For Prophylaxis Of IFDs In Adult Patients Undergoing Allogeneic HSCT; Study Meets Primary Endpoint

CorMedix: A Shrinking Core And No Proven Second Engine

CorMedix: Waiting On Phase III ReSPECT For A Further Re-Rating (Upgrade)

CorMedix Inc. (CRMD) Q4 2025 Earnings Call Transcript

CorMedix Inc (NASDAQ:CRMD) Shares Drop on Q4 2025 Earnings Miss

CorMedix shares are trading lower after the company reported mixed Q4 financial results.

CorMedix shares are trading lower after the company reported mixed Q4 financial results.

CORRECTION: Cormedix Affirms FY2026 Sales Guidance of $300.000M-$320.000M

Cormedix Earnings Review: Q4 Summary